Related Experiment Video
Updated: Oct 6, 2025
Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine
Published on: February 24, 2023
The Pellino1-PKCθ Signaling Axis Is an Essential Target for Improving Antitumor CD8+ T-lymphocyte Function
Jihyun Park1, Si-Yeon Lee2, Yoon Jeon2,3
1Department of Health Sciences and Technology, SAIHST, Sungkyunkwan University, Seoul, Republic of Korea.
Abstract:
CD8+ T cells play an important role in the elimination of tumors. However, the underlying mechanisms involved in eliciting and maintaining effector responses in CD8+ T cells remain to be elucidated. Pellino1 (Peli1) is a receptor signal-responsive ubiquitin E3 ligase, which acts as a critical mediator for innate immunity. Here, we found that the risk of developing tumors was dependent on Peli1 expression. Peli1 was upregulated in CD8+ T cells among tumor-infiltrating lymphocytes (TIL). In contrast, a deficit of Peli1 enhanced the maintenance and effector function of CD8+ TILs. The development of Peli1-deficient CD8+ TILs prevented T-cell exhaustion and retained the hyperactivated states of T cells to eliminate tumors. We also found that Peli1 directly interacted with protein kinase C-theta (PKCθ), a central kinase in T-cell receptor downstream signal transduction, but whose role in tumor immunology remains unknown. Peli1 inhibited the PKCθ pathway by lysine 48-mediated ubiquitination degradation in CD8+ TILs. In summary, the Peli1-PKCθ signaling axis is a common inhibitory mechanism that prevents antitumor CD8+ T-cell function, and thus targeting Peli1 may be a useful therapeutic strategy for improving cytotoxic T-cell activity.
Insights
Pellino1 (Peli1) negatively regulates anti-tumor CD8+ T cell responses. Reducing Peli1 enhances T cell function and prevents exhaustion, suggesting Peli1 as a therapeutic target for cancer immunotherapy.
Area of Science:
- Immunology
- Molecular Biology
- Cancer Research
Background:
- CD8+ T cells are crucial for tumor elimination.
- Mechanisms maintaining CD8+ T cell effector function in tumors are not fully understood.
- Pellino1 (Peli1) is an E3 ligase involved in innate immunity signaling.
Purpose of the Study:
- To investigate the role of Peli1 in CD8+ T cell responses within the tumor microenvironment.
- To elucidate the molecular mechanisms by which Peli1 affects anti-tumor immunity.
- To evaluate Peli1 as a potential therapeutic target for cancer immunotherapy.
Main Methods:
- Analysis of Peli1 expression in tumor-infiltrating lymphocytes (TILs).
- Assessment of CD8+ TIL function in Peli1-deficient versus wild-type mice.
- Investigation of Peli1 interaction with protein kinase C-theta (PKCθ) using ubiquitination assays.
Main Results:
- Peli1 expression is elevated in CD8+ TILs and correlates with tumor risk.
- Peli1 deficiency enhances CD8+ TIL maintenance, effector function, and prevents T cell exhaustion.
- Peli1 directly interacts with PKCθ and inhibits its signaling pathway via ubiquitination and degradation.
- The Peli1-PKCθ axis suppresses anti-tumor CD8+ T cell activity.
Conclusions:
- The Peli1-PKCθ signaling pathway is a key negative regulator of anti-tumor CD8+ T cell immunity.
- Targeting Peli1 presents a promising therapeutic strategy to enhance cytotoxic T cell activity against tumors.
Related Concept Videos
01:19Interactions Between Signaling Pathways
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
01:27Tumor Immunotherapy
01:31The Intrinsic Apoptotic Pathway